System-Specific Biopharmaceuticals

GlaxoSmithKline plc

GSK repurchased 8,663,000 shares

WRN Inhibitor Market Entering Growth Phase

GSK Buys Back 8,329,000 Shares Under Repurchase Program

GSK to Present 21 Abstracts on Liver Disease Treatments at 2025 AASLD Meeting

JPMorgan Analyst Reiterates Sell Rating on GSK

Papadakis and Barclays Maintain Hold Rating on GSK

Leuchten and TR | OpenAI – 4o Reiterate Buy Rating on GlaxoSmithKline

GSK Executives Sell Shares

Deutsche Bank Maintains Hold Rating on GlaxoSmithKline

GSK turns profitable in Q3 with revenue growth

GSK Receives EU Orphan Drug Designation for Lung Cancer Treatment

GSK Secures Global Exclusive Rights to COPD Candidate Drug

GSK Obtains Exclusive Rights to Prostate Cancer Antibody-Drug Conjugate from Syndivia

Ebrahim Analyst's Rating on GlaxoSmithKline Draws Attention

Sachin Jain Gives GlaxoSmithKline's Blenrep a Sell Rating

GSK's Blenrep Receives FDA Reapproval for Relaunch

Weston Provides Ratings for Healthcare Industry Stocks

GSK's Next-Generation Low-Carbon Ventolin Inhaler Shows Positive Results in Phase 3 Clinical Trials

GSK and ViiV Healthcare Invest £6 Million to Support Health Initiatives in Low-Income Countries

GSK Announces Successful Phase III Trial Results for Tebipenem HBr

On November 14, 2025, GSK plc bought 8.83 million shares, raising its treasury shares to 256.29 million, which is 6.31% of total voting rights.1GSK Egypt's consolidated profit dropped 71.46% year-on-year to EGP 30.207 million in 2025, despite revenue rising to EGP 2.893 billion from EGP 2.143 billion.2

TradingView

Key facts: GSK Acquires 8.83M Shares; Egypt Profit Falls 71.46%

On November 13, 2025, GSK plc bought 8,663,000 shares in its buyback program, increasing total treasury shares to 256,127,844, or 6.31% of voting rights.1On November 13, 2025, GSK plc announced a transaction notification concerning the shareholding of its directors and Persons Discharging Managerial Responsibilities (PDMR).2

Key facts: GSK plc buys 8.6M shares; announces director shareholding update

AVVIY

UK stocks fell due to weak GDP data, mixed earnings, and ex-dividend trading. FTSE 100 dropped 1.1%, FTSE 250 fell 0.6%, and AIM All-Share slid 1.0%. UK GDP grew 0.1% in Q3, missing forecasts. Analysts expect BoE rate cuts. Sterling rose against USD. European and US markets also declined. GSK, BP, Shell, and Sainsbury traded ex-dividend. 3i Group and Aviva faced declines due to disappointing results. Convatec and Endeavour Mining rose on positive updates. Gold and Brent oil prices increased.

marketscreener

Aviva

Stocks fall amid weak GDP print ahead of budget

GSK.WI

On November 12, 2025, GSK plc bought 8,496,000 shares, increasing its treasury shares to 255,960,844, which is 6.31% of total voting rights.1AN2 Therapeutics collaborates with GSK to develop boron-based LeuRS inhibitors for tuberculosis, supported by a third year of funding from the Gates Foundation.2On November 12, 2025, GSK PLC announced its block listing six monthly return, detailing its compliance and engagement with the London Stock Exchange.3

GSK plc Sponsored ADR

Key facts: GSK Increases Treasury Shares; Partners with AN2 on TB Drug; Announces Block Listing

The WRN inhibitors market is entering a growth phase, driven by early-stage clinical programs targeting DNA repair vulnerabilities in precision oncology. Key candidates like NDI-219216, GSK4418959, and HRO761 are in development for treating MSI-high tumors, with significant market potential projected by 2040. Advances in genetic testing and promising early clinical data are fueling interest in this niche segment. Leading companies such as Nimbus Therapeutics and GlaxoSmithKline are at the forefront, highlighting the therapeutic innovation opportunities in this emerging market.

prnewswire

17:31 ET
			
			
				WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight

On November 11, 2025, GSK plc bought 8,329,000 shares in its buyback program, totaling 255,793,844 treasury shares, or 6.30% of voting rights.1GSK's stock rose by 3% as part of a broader increase in the pharmaceutical and healthcare sectors, which both gained more than 2.5% amid positive market conditions.2

Key facts: GSK Buys 8.3M Shares; Stock Rises 3% in Market Surge

On November 10, 2025, GSK plc bought 8,159,000 shares, raising its treasury shares to 255,623,844, which is 6.30% of total voting rights.1On November 10, 2025, GSK plc announced provisional dividend dates for the year 2026, with a note that these dates are subject to change.2

Key facts: GSK plc acquires 8.16M shares; announces 2026 dividend dates

GSK plc has published provisional dividend dates for 2026, which are subject to change. Key dates include: Q1 results on April 29, 2026, with ex-dividend dates on May 14 and 15, and payable on June 18. Q2 results on July 29, 2026, with ex-dividend dates on August 13 and 14, and payable on September 17. Q3 results on October 28, 2026, with ex-dividend dates on November 12 and 13, and payable on December 14. Q4 results on February 3, 2027, with ex-dividend dates on February 18 and 19, and payable on March 16.

London Stock Exchange

REG - GSK PLC - GSK publishes provisional dividend dates

Shares of biopharma firm AN2 Therapeuticsrise 12.2% to $1.24 premarketCompany enters a collaboration agreement with GSK (GSK.L) to develop new therapies for tuberculosisUnder the agreement, the Gates Foundation will provide a third year of funding to support AN2’s work within the collaborationAs of last close, stock down 17.4% YTD

Reuters

BUZZ-AN2 Therapeutics jumps after GSK collaboration to develop tuberculosis treatment

ANTX

AN2 Therapeutics Inc. has partnered with GSK to develop boron-based LeuRS-inhibitors for tuberculosis treatment, supported by funding from the Gates Foundation. This collaboration aims to create innovative therapies for TB, focusing on the needs of patients in lower-income countries. The partnership combines AN2’s boron chemistry platform with GSK’s global health expertise to address urgent treatment gaps.

AN2 Therapeutics

AN2 Therapeutics Partners with GSK to Develop Boron-Based Tuberculosis Treatments

GSK plc announced the purchase of 170,000 ordinary shares at prices ranging from 1,757.50p to 1,788.50p on November 7, 2025, as part of its buyback program. This purchase increases the total shares bought since September 30, 2025, to 8,159,000. Following this transaction, GSK holds 255,623,844 shares in treasury, with a total of 4,059,804,530 shares issued. The percentage of voting rights attributable to treasury shares is now 6.30%.

REG - GSK PLC - Transaction in Own Shares

China's biopharmaceutical sector is experiencing a significant investment boom, driven by major licensing deals and advancements in antibody-drug conjugate (ADC) therapies. Notable transactions include MSD's $175 million deal with Sichuan Kelun-Biotech and Aiolos' licensing of an asthma treatment from Jiangsu Hengrui Pharmaceuticals, which led to a $1 billion acquisition by GSK. The Hang Seng Biotech index surged 112% this year, reflecting the sector's growth. Chinese firms secured 103 out-licensing deals worth $92 billion in 2023, showcasing their competitive edge in drug development and a shift towards self-sufficiency in therapeutics.

南华早报

6 of the best: how China’s new biotech vanguard is banking billions from breakthroughs

GSK plc announced 21 abstracts on liver condition treatments for the AASLD 2025 meeting, including Phase II results for efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH) and a sub-analysis from the B-Sure study on chronic hepatitis B. The efimosfermin results support the Phase III ZENITH-1 and ZENITH-2 trials. Additional findings include GSK4532990 for alcohol-associated liver disease and data on linerixibat for cholestatic pruritus in primary biliary cholangitis. All results will be presented at the meeting from November 7-11 in Washington D.C.

GSK Unveils Promising Phase II Results for Efimosfermin in MASH at AASLD 2025

J.P. Morgan analyst Zain Ebrahim has reaffirmed a Sell rating on GlaxoSmithKline (GSK) with a price target of £15.00. This follows a similar Sell rating from Bank of America Securities. In contrast, Bernstein maintained a Buy rating on GSK. Ebrahim is ranked #8311 out of 10072 analysts according to TipRanks.

Key facts: GSK Acquires 8.83M Shares; Egypt Profit Falls 71.46%

Key facts: GSK plc buys 8.6M shares; announces director shareholding update

Stocks fall amid weak GDP print ahead of budget

Key facts: GSK Increases Treasury Shares; Partners with AN2 on TB Drug; Announces Block Listing

17:31 ET WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight